Resistance to Targeted Anti-Cancer Therapeutics

Resistance to Immunotherapeutic Antibodies in Cancer

Strategies to Overcome Resistance

Editors: Bonavida, Benjamin (Ed.)

  • ​​​​​​​​​​​Summarizes common and unique features of mAbs against various cancers  
  • Explores the latest developments on the molecular, biochemical and genetic mechanisms of resistance by various mAbs 
  • Covers the potential use of the combination treatment of mAbs with other drugs/mAbs to reverse resistance 
see more benefits

Buy this book

eBook $149.00
price for USA (gross)
  • ISBN 978-1-4614-7654-2
  • Digitally watermarked, DRM-free
  • Included format: PDF, EPUB
  • ebooks can be used on all reading devices
  • Immediate eBook download after purchase
Hardcover $189.00
price for USA
  • ISBN 978-1-4614-7653-5
  • Free shipping for individuals worldwide
  • Usually dispatched within 3 to 5 business days.
About this book

​​​​The traditional approaches to treat various cancers include chemotherapy, radiation and/or hormonal therapy. While these therapies continue to be effective in large part, they are not selective and highly toxic. There have been encouraging results in alternative therapeutic approach called antibody-mediated anti-cancer therapy, which is less toxic, more selective, and can also reverse drug/radiation resistance. Monoclonal antibodies or mAbs can be used to destroy malignant tumor cells and prevent tumor growth by blocking specific cell receptors. mAbs can bind only to cancer cell-specific antigens and induce an immunological response against the target cancer cell. The book covers the common and unique features of mAbs agains various cancer, gives the latest developments on the molecular, biochemical and genetic mechanisms of resistance by various mAbs, as well as discuss novel mAbs to overcome resistance.

About the authors

Dr. Benjamin Bonavida is a professor at UCLA's David Geffen School of Medicine for the Department of Microbiology, Immunology, & Molecular Genetics. His other appointments include being a member of the Department of Defense Congressionally Directed Medical Research Program, Member of the National Cancer Institute's SPORE Program, member of the International Scientific Advisory Board of the Israel Cancer Research Foundation, to name a few. He's currently a scientific reviewer for several journals and a member of editorial boards including Journal of Clinical Immunology, International Journal of Oncology, and Cancer Biotherapy & Radiopharmaceuticals. In his career, he's published over 450 papers and reviews, and he's also edited two books with Springer in the past. For more information, please see the CV attached herewith.

Table of contents (10 chapters)

  • Resistance to Anticancer Antibodies: From Mechanisms to Solutions

    Reslan, Lina (et al.)

    Pages 1-24

  • Tumor Antigen-Specific Monoclonal Antibody-Based Immunotherapy, Cancer Initiating Cells and Disease Recurrence

    Wang, Yangyang (et al.)

    Pages 25-47

  • Overcoming Resistance to Therapeutic Antibodies by Targeting Fc Receptors

    Williams, Emily L. (et al.)

    Pages 49-71

  • Understanding the Mechanisms of Resistance to Rituximab: Paving the Road for the Development of Therapeutic Strategies to Overcome Rituximab-Resistance

    Hernandez-Ilizaliturri, Francisco J. (et al.)

    Pages 73-92

  • Tumor Resistance to Antibody-Mediated Immunotherapy and Reversal of Resistance: Rituximab as Prototype

    Bonavida, Benjamin

    Pages 93-124

Buy this book

eBook $149.00
price for USA (gross)
  • ISBN 978-1-4614-7654-2
  • Digitally watermarked, DRM-free
  • Included format: PDF, EPUB
  • ebooks can be used on all reading devices
  • Immediate eBook download after purchase
Hardcover $189.00
price for USA
  • ISBN 978-1-4614-7653-5
  • Free shipping for individuals worldwide
  • Usually dispatched within 3 to 5 business days.
Loading...

Recommended for you

Loading...

Bibliographic Information

Bibliographic Information
Book Title
Resistance to Immunotherapeutic Antibodies in Cancer
Book Subtitle
Strategies to Overcome Resistance
Editors
  • Benjamin Bonavida
Series Title
Resistance to Targeted Anti-Cancer Therapeutics
Series Volume
2
Copyright
2013
Publisher
Springer-Verlag New York
Copyright Holder
Springer Science+Business Media New York
eBook ISBN
978-1-4614-7654-2
DOI
10.1007/978-1-4614-7654-2
Hardcover ISBN
978-1-4614-7653-5
Series ISSN
2196-5501
Edition Number
1
Number of Pages
XIII, 202
Topics